Overview of Szutowicz et al. (Neurochem Res 38(8):1523-1542, 2013), is focusing on specific features of acetyl-CoA metabolism in the cholinergic compartment of the brain. Authors are suggesting that deficit of that metabolite can act as a trigger for several cholinergic encephalopathies, with special emphasis on Alzheimer disease (AD). Central role of acetyl-CoA and its metabolic paths in neurodegeneration are charted starting from its synthesis in mitochondria, followed by utilization in energy metabolism, as well as transport into cytoplasm and participation in the synthesis and turnover of neurotransmitter acetylcholine to emergence of diseased states. Various putative pathogenic signals are evaluated that might be responsible for acetyl-CoA deficit ending up in development of neurodegeneration, unraveling exceptional susceptibility of cholinergic system. They are discussed in context of other existing alternative hypotheses on AD etiology. Overview is thoroughly documented (178 references) and is supported by results accomplished by extensive research in Prof. Szutowicz's laboratory (approximately 25 original papers).

Laboratory of Biochemistry and Brain Pathophysiology Prague Psychiatric Center Ústavní 91 181 03 Prague Czech Republic

Zobrazit více v PubMed

Eur J Nucl Med Mol Imaging. 2008 Mar;35 Suppl 1:S30-45 PubMed

Neurochem Res. 2003 Nov;28(11):1705-13 PubMed

Psychopharmacology (Berl). 2006 Nov;188(4):509-20 PubMed

Neurochem Res. 2003 Oct;28(10):1563-74 PubMed

Neurochem Res. 2001 Apr;26(4):353-61 PubMed

Neurosci Lett. 1995 Dec 1;201(1):81-3 PubMed

Neurochem Res. 2007 Apr-May;32(4-5):739-50 PubMed

Trends Neurosci. 1993 Oct;16(10):409-14 PubMed

J Neural Transm (Vienna). 2004 Mar;111(3):281-94 PubMed

Science. 1973 May 4;180(4085):511-3 PubMed

Neurochem Res. 2004 Mar;29(3):493-504 PubMed

Lancet. 1976 Dec 25;2(8000):1403 PubMed

Lancet. 1977 Jan 22;1(8004):189 PubMed

Int J Alzheimers Dis. 2012;2012:731526 PubMed

Neurochem Res. 2007 Oct;32(10):1640-5 PubMed

Neurochem Res. 2012 Dec;37(12):2627-58 PubMed

Neurochem Res. 1990 Dec;15(12):1239-45 PubMed

Trends Neurosci. 2002 Jan;25(1):22-6 PubMed

Neurochem Int. 1985;7(2):369-72 PubMed

Neurochem Res. 2009 Oct;34(10):1824-9 PubMed

J Neural Transm (Vienna). 1998;105(4-5):415-22 PubMed

J Neurosci. 2001 May 1;21(9):3017-23 PubMed

Science. 2002 Jul 19;297(5580):353-6 PubMed

Science. 1982 Mar 5;215(4537):1237-9 PubMed

Neurochem Res. 2013 Aug;38(8):1523-42 PubMed

Neurochem Int. 2013 Apr;62(5):575-94 PubMed

Am J Med. 2000 Nov;109(7):577-85 PubMed

Brain. 1976 Sep;99(3):459-96 PubMed

Exp Neurol. 2000 Jun;163(2):495-529 PubMed

Neurochem Int. 2002 May;40(6):527-31 PubMed

Neurochem Res. 2011 Jul;36(7):1149-56 PubMed

Neurochem Res. 2003 Oct;28(10):1495-9 PubMed

J Diabetes Sci Technol. 2008 Nov;2(6):1101-13 PubMed

Neurochem Res. 2005 Jun-Jul;30(6-7):895-908 PubMed

Neuroscience. 1985 Jan;14(1):1-14 PubMed

Neurochem Res. 2007 Oct;32(10):1749-56 PubMed

Neurochem Res. 1994 Sep;19(9):1131-7 PubMed

Hum Mol Genet. 2009 Oct 15;18(R2):R137-45 PubMed